Engineered monoclonal antibody tobevibart enhances HBsAg capture by Fc receptor-positive cells and activates HBV-specific T cells
- 27 August 2025
- journal article
- Published by Elsevier in Journal of Hepatology
- Vol. 84 (1) , 62-73
Abstract
No abstract availableKeywords
Funding Information
- University of Utah
- VIR Biotechnology Inc
This publication has 25 references indexed in Scilit:
- The lack of HBsAg secretion does neither facilitate induction of antiviral T cell responses nor Hepatitis B Virus clearance in miceAntiviral Research, 2024
- Potent broadly neutralizing antibody VIR-3434 controls hepatitis B and D virus infection and reduces HBsAg in humanized miceJournal of Hepatology, 2023
- How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?Journal of Hepatology, 2022
- Immunobiology and pathogenesis of hepatitis B virus infectionNature Reviews Immunology, 2021
- Fc-optimized antibodies elicit CD8 immunity to viral respiratory infectionNature, 2020
- Viral envelope-specific antibodies in chronic hepatitis B virus infectionCurrent Opinion in Virology, 2018
- T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significanceCell Death & Disease, 2015
- Distinct kinetics and dynamics of cross-presentation in liver sinusoidal endothelial cells compared to dendritic cells #Hepatology, 2009
- In vitro use of autologous dendritic cells improves detection of T cell responses to hepatitis B virus (HBV) antigensJournal of Medical Virology, 2008
- Receptor-mediated endocytosis of immune complexes in rat liver sinusoidal endothelial cells is mediated by FcγRIIb2Hepatology, 2007